Tyler J Nielsen

6PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

|Jun 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.

David B Page, Joanna Pucilowska, Brie Chun

|Apr 06, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.

Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz

|Feb 22, 2023
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.

Tyler J Nielsen, Matthew G Varga, Catherine T Cronister

|Oct 13, 2021
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.

Toshiaki Iwase, Kim R M Blenman, Xiaotong Li

|May 01, 2020
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.

Jose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee

Pageof 1

Frequent Collaborators

4 joint publications

Robert Seitz

4 joint publications

Brock L Schweitzer

2 joint publications

Naoto T Ueno

2 joint publications

Lajos Pusztai